DOI: 10.12890/2021_003099

Secukinumab, Pituitary Enlargement and Panhypopituitarism: Are They Related?

Authors

  • Diogo Ramalho Endocrinology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal
  • André Araújo Neuroradiology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal
  • Gustavo Rocha Endocrinology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal
  • Filipa Duarte-Ribeiro Internal Medicine Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal

silva.josediogo@gmail.com

Keywords

Pituitary neoplasms, hypophysitis, hypopituitarism, secukinumab

Abstract

Pituitary adenomas are the most common cause of hypopituitarism associated with pituitary enlargement, but other aetiologies have been emerging, namely immune checkpoint inhibitor-induced hypophysitis (ipilimumab, nivolumab and pembrolizumab). Secukinumab is a recently approved human monoclonal antibody used for the treatment of psoriasis, with no know reported cases of hypophysitis. We describe a challenging case of panhypopituitarism in a patient with a pituitary incidentaloma and a temporal relationship between secukinumab initiation and the manifestation of clinical features suggestive of hypopituitarism. In such intricate work-up, the differential diagnoses should be carefully considered, taking into account the therapeutic and prognostic implications.

View the entire article

Downloads

References

  1. Gutenberg A, Larsen J, Lupi I, Rohde V, Caturegli P. A radiologic score to distinguish autoimmune hypophysitis from nonsecreting pituitary adenoma preoperatively. AJNR Am J Neuroradiol 2009;30(9):1766–1772.
  2. Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, et al. Pituitary incidentaloma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96(4):894–904.
  3. Joshi MN, Whitelaw BC, Carroll PV. MECHANISMS IN ENDOCRINOLOGY: Hypophysitis: diagnosis and treatment. Eur J Endocrinol 2018;179(3):R151–R163.
  4. Yang EJ, Beck KM, Liao W. Secukinumab in the treatment of psoriasis: patient selection and perspectives. Psoriasis (Auckl) 2018;8:75–82.
  5. Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med 2016;22(3):230–241.
  6. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61(12):1693–1700.
  7. Ramos-Levi AM, Gargallo M, Serrano-Somavilla A, Sampedro-Nunez MA, Fraga J, Marazuela M. Hypophysitis following treatment with ustekinumab: radiological and pathological findings. Front Endocrinol (Lausanne) 2018;9:83.
  8. Esposito D, Olsson DS, Ragnarsson O, Buchfelder M, Skoglund T, Johannsson G. Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary 2019;22(4):422–434.

Published

2021-12-31

Issue

Vol. 8 No. 12 (2021)

How to Cite

1.
Ramalho D, Araújo A, Rocha G, Duarte-Ribeiro F. Secukinumab, Pituitary Enlargement and Panhypopituitarism: Are They Related? EJCRIM [Internet]. 2021 Dec. 31 [cited 2026 Nov. 3];8(12). Available from: https://ejcrim.com/index.php/ejcrim/article/view/3099